(Q53921000)
Statements
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer (English)
Bernard A Zonnenberg
Gerard Groenewegen
Todd J Janus
Terri W Leahy
Rod A Humerickhouse
Jeffrey D Isaacson
Robert A Carr